FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease.
- DOI
- 10.1002/jcph.70257
- Published
- 2026 Aug
- Container
- Journal of clinical pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/jcph.70257,
title = {FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease.},
author = {Delvadia PR and Nookala AR and Gottipati G and Sabarinath S and Uppoor RS and Mehta MU and Du X and Wang YC and Dokmanovic M and Myers R and Stevens J and Baldassari L and Lee P and Jawidzik L and Apparaju S and Seo S and Brahme NN and Schrieber SJ},
year = {2026},
journal = {Journal of clinical pharmacology},
doi = {10.1002/jcph.70257},
url = {https://doi.org/10.1002/jcph.70257}
}RIS
TY - JOUR TI - FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. AU - Delvadia PR AU - Nookala AR AU - Gottipati G AU - Sabarinath S AU - Uppoor RS AU - Mehta MU AU - Du X AU - Wang YC AU - Dokmanovic M AU - Myers R AU - Stevens J AU - Baldassari L AU - Lee P AU - Jawidzik L AU - Apparaju S AU - Seo S AU - Brahme NN AU - Schrieber SJ PY - 2026 JO - Journal of clinical pharmacology DO - 10.1002/jcph.70257 UR - https://doi.org/10.1002/jcph.70257 ER -
APA
PR, D., AR, N., G, G., S, S., RS, U., MU, M., X, D., YC, W., M, D., R, M., J, S., L, B., P, L., L, J., S, A., S, S., NN, B., & SJ, S. (2026). FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease.. Journal of clinical pharmacology. https://doi.org/10.1002/jcph.70257
Source records
- pubmed · retrieved 2026-09-26T21:39:39.750Z